证券代码：002294 证券简称：信立泰 编号：2025-032 深圳信立泰药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第六届董事会第十一次会议 于 2025 年 5 月 24 日下午 14 时，以通讯及书面方式召开，会议通知于 2025 年 5 月 21 日以电子邮件方式送达。应参加董事 9 人，实际参加董事 9 人，其中，叶 宇翔、叶澄海、刘来平以书面方式出席会议，出席董事符合法定人数。经半数以 上董事共同推举，会议由董事杨健锋先生主持，本次会议召开符合法律法规和《公 司章程》等有关规定。 与会董事审议并形成如下决议： 特此公告 深圳信立泰药业股份有限公司 董事会 二〇二五年五月二十七日 一、 会议以 9 人同意，0 人反对，0 人弃权，审议通过了《关于与国为生物 签署协议暨获得 GW906 独家许可权益的议案》。 同意公司与成都国为生物医药有限公司（下称"国为生物"）签订协议，获 得国为生物拥有的在研 AGT-siRNA 药物 GW906 的原料药及制剂相关知识产权、 技术信息（下称"许可产 ...

证券代码：002294 证券简称：信立泰 编号：2025-033 深圳信立泰药业股份有限公司 关于获得 AGT-siRNA 药物 GW906 独家许可权益的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、交易概述 （一） 基本情况 为进一步丰富公司在慢病领域的创新产品管线，深圳信立泰药业股份有限公 司（下称"公司"或"信立泰"）拟与成都国为生物医药有限公司（下称"国为 生物"）签订协议，获得国为生物在研 AGT-siRNA 药物 GW906 的原料药及制 剂相关知识产权、技术信息（下称"许可产品"或"GW906"）于中国市场（即 大陆、台湾地区、香港及澳门特别行政区，下同）的独家许可权益，包括但不限 于产品的研发、注册、生产及商业化等。 公司将根据交易进度和研发进展情况以自筹资金付款。其中，首付款及研发 里程碑款总金额最高不超过 18,000 万元。如该产品获批上市销售，且产品净销 售额（以自然年度计）首次达到协议约定数额，公司支付销售里程碑款，销售里 程碑累计最高不超过 37,000 万元。同时，在协议约定期限内，公司根据年度净销 售额按一定比例向 ...

证券代码：002294 证券简称：信立泰 编号：2025-032 深圳信立泰药业股份有限公司 第六届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第六届董事会第十一次会议 于 2025 年 5 月 24 日下午 14 时，以通讯及书面方式召开，会议通知于 2025 年 5 月 21 日以电子邮件方式送达。应参加董事 9 人，实际参加董事 9 人，其中，叶 宇翔、叶澄海、刘来平以书面方式出席会议，出席董事符合法定人数。经半数以 上董事共同推举，会议由董事杨健锋先生主持，本次会议召开符合法律法规和《公 司章程》等有关规定。 与会董事审议并形成如下决议： 一、会议以 9 人同意，0 人反对，0 人弃权，审议通过了《关于与国为生物 签署协议暨获得 GW906 独家许可权益的议案》。 同意公司与成都国为生物医药有限公司（下称"国为生物"）签订协议，获 得国为生物拥有的在研 AGT-siRNA 药物 GW906 的原料药及制剂相关知识产权、 技术信息（下称"许可产品"或"GW906"）于中国市场（即大 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [7][17]. Core Insights - The company achieved a revenue of 4.01 billion yuan in 2024, representing a year-on-year growth of 19.22%, while the net profit attributable to shareholders was 601.57 million yuan, up 3.71% year-on-year [1]. - In Q1 2025, the company reported a revenue of 1.06 billion yuan, a slight decline of 2.64% year-on-year, with a net profit of 200 million yuan, showing a marginal increase of 0.03% [1]. - The sales expense ratio increased to 36.71% in 2024, primarily due to higher promotional costs for newly launched products [2]. - The company is focusing on optimizing its revenue structure, with a notable increase in the proportion of patented and new products, which are expected to drive future growth [3]. Financial Performance - The company’s revenue for 2025 is projected to be 4.54 billion yuan, with a growth rate of 13.10%, and net profit is expected to be 661.81 million yuan, reflecting a growth rate of 10.01% [5][11]. - The R&D investment for 2024 was 1.02 billion yuan, accounting for 25.35% of revenue, indicating a strong commitment to innovation [4]. - The company’s EBITDA for 2024 is estimated at 1.73 billion yuan, with a net profit margin of 14.99% [11][12]. Product and Pipeline Development - The company has four projects in the NDA stage and three in Phase III clinical trials, showcasing a robust pipeline for future growth [4]. - New products such as复立坦 and 信立汀他 have entered the national medical insurance catalog, laying a foundation for future sales growth [3]. Market Position and Strategy - The company is increasing its market presence through enhanced sales efforts and product promotion, particularly in the competitive hypertension medication market [3][4]. - The revenue from formulations reached 3.19 billion yuan in 2024, up 20.43%, while raw materials and intermediates saw a slight decline [3].

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company achieved a revenue of 4.012 billion yuan in 2024, representing a year-on-year growth of 19.22%, while the net profit attributable to the parent company was 601.57 million yuan, up 3.71% year-on-year [1]. - In Q1 2025, the company reported a revenue of 1.062 billion yuan, a slight decline of 2.64% year-on-year, with a net profit of 200 million yuan, showing a marginal increase of 0.03% [1]. - The sales expense ratio increased to 36.71% in 2024, primarily due to higher promotional costs for newly launched products [2]. - The revenue structure is shifting towards patented and new products, with a notable increase in the revenue scale of these segments [3]. - The company invested 1.017 billion yuan in R&D in 2024, accounting for 25.35% of its revenue, indicating a strong commitment to innovation [4]. Financial Performance - The projected revenues for 2025, 2026, and 2027 are 4.538 billion, 5.423 billion, and 6.246 billion yuan, respectively, with net profits adjusted to 662 million and 783 million yuan for 2025 and 2026 [5]. - The company’s EBITDA for 2024 is estimated at 1.727 billion yuan, with a net profit margin of 14.99% [6][11]. - The company’s total assets are projected to reach 10.168 billion yuan by 2025, with a debt-to-asset ratio of 17.35% [11][12]. Product and Market Development - The company is focusing on expanding its product pipeline, with several projects in various clinical stages, including four in the NDA phase and three in Phase III clinical trials [4]. - New products like复立坦 and 信立汀他 have entered the national medical insurance catalog, laying a foundation for future growth [3]. - The company’s flagship product, 信立坦, continues to gain market share in the competitive hypertension drug market, particularly in grassroots markets [3].

Group 1 - The market experienced a slight adjustment last week, with the brand index closing at 1657.60 points, while several component stocks rose against the trend, including Xinlitai, Tigermed, and Stone Technology [1][2] - Xinlitai led the gains with an increase of 14.96%, followed by Tigermed at 12.48%, and Stone Technology at 11.47%. Other notable gainers included Three Squirrels and Supor, which rose by 7.69% and 6.07% respectively [2] - Since the beginning of 2025, Maimai Biological has seen a significant increase of 51.27%, with Shanghai Jahwa and Xinlitai also showing strong performance with gains of 47.96% and 47.71% respectively [3] Group 2 - Looking ahead, the market is expected to gradually shift towards a more positive trend as investors remain sensitive to favorable factors, with ongoing accumulation of positive elements supporting economic expectations and fundamentals [4] - The current market structure indicates a potential for mid-term positive performance, driven by policy support, domestic technological breakthroughs, and a favorable external environment, which may enhance liquidity in the domestic capital market [4] - In the medium to long term, opportunities may arise in sectors such as domestic demand, technology, and overseas expansion, with a focus on defensive dividend sectors and aggressive technology sectors, including internet and robotics [5]

Market Performance - On May 23, major market indices experienced fluctuations and closed lower, with A-shares trading volume reaching 1.18 trillion yuan, and over 1,100 stocks closing higher, including 52 stocks hitting the daily limit [1] - For the week, the Shanghai Composite Index fell by 0.57%, the ChiNext Index dropped by 0.88%, and the STAR Market 50 Index decreased by 1.47% [1] Individual Stock Performance - Over 1,600 stocks rose this week, with 22 stocks gaining over 30%. Notably, six stocks surged over 50%, with the largest increase being 99.96% for Sanofi [1][2] - Other significant gainers included Huibo Yuntong (301316) and Binhai Energy (000695), both of which saw weekly increases exceeding 60% [1][2] Sector Analysis - Among the stocks that rose over 30%, the pharmaceutical and biological sector had six representatives, followed by light industry manufacturing with three stocks [1] Historical Highs - On May 23, 17 stocks reached historical closing highs, with the pharmaceutical and biological, mechanical equipment, and automotive sectors showing a concentration of high performers [3][4] - The average increase for stocks reaching historical highs was 8.20%, with notable gainers including Xintiandi (301277) and Zhongzhou Special Materials (300963) [3] Institutional Activity - On May 23, ten stocks saw net purchases from institutions, with Yixin Tang (002727) leading at a net buy of 102 million yuan [5][6] - Conversely, institutions sold off stocks such as Hongchuang Holdings (002379) and Tianqimo (002510), each experiencing net sales exceeding 50 million yuan [5][6] Northbound Capital Flow - Northbound capital was present in nine stocks on the trading board, with net purchases in three stocks: Xue Ren Shares (002639), Huibo Yuntong, and Jinlongyu (002882) [7] - Yixin Tang faced the highest net sell-off from northbound capital, totaling 68.98 million yuan [7] Company Announcements - Zhongjin Gold (600489) plans to inject four companies, including Inner Mongolia Jintao, into the company to resolve competition issues [8] - Huakang Clean (301235) won a bid for a healthcare project with a contract value of 60.24 million yuan and a duration of 120 days [8] - Weier Shares (603501) intends to issue H-shares and list on the Hong Kong Stock Exchange [9] - Yunchongma (603130) plans to raise no more than 640 million yuan for a project to produce DTY silk and high-performance leather base fabric [9]

证券代码：002294 证券简称：信立泰 编号：2025-031 深圳信立泰药业股份有限公司 关于第二期员工持股计划出售完毕暨终止的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳信立泰药业股份有限公司（下称"公司"）第二期员工持股计划委托国 联证券资产管理有限公司设立单一资产管理计划进行管理。鉴于资管计划存续期 已于 2025 年 5 月 23 日届满，第二期员工持股计划所持剩余股份全部出售完毕。 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》、深圳证券 交易所《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》等有关要求，现就有关情况公告如下： 一、 第二期员工持股计划概述 1、公司分别于 2020 年 12 月 27 日、2021 年 1 月 21 日召开第五届董事会第 九次会议、2021 年第一次临时股东大会，审议通过了《关于〈深圳信立泰药业股 份有限公司第二期员工持股计划（草案）及摘要〉的议案》等相关议案。 4、本期员工持股计划所获标的股票自公司公告最后一笔标的股票过户至本 期员工持股计划名下之日起至满 ...

一、行情回顾 市场全天冲高回落，三大指数午后集体跳水。可控核聚变概念表现活跃，王子新材、尚纬股份、融发核电等多股涨停。创新药概念股再度大涨，海辰药业、 众生药业等封板，信立泰、科伦药业创历史新高。下跌方面，航运港口板块延续跌势，南京港、连云港跌停；电力股集体调整，西昌电力、乐山电力跌停。 个股跌多涨少，沪深京三市下跌个股超4200只，今日成交1.18万亿。 二、当日热点 1.核聚变 核聚变板块今日继续大涨，王子新材、中洲特材等继续涨停，尚纬股份2连板，融发核电涨停。 5月23日，行情数据显示，美核电股盘后集体大涨。Altman持股的Oklo涨幅从15.63%收窄至12.54%，Centrus能源涨12.4%，Nuscale涨10.15%，Uranium能源 涨8.14%等。 新浪财经消息称，称特朗普将签署核能命令，这些行政命令将试图简化新反应堆审批的监管流程，并加强燃料供应链。 国内方面核电领域近期也迎来重大催化。国家能源局近日发布关于促进能源领域民营经济发展若干举措的通知。其中提到，支持民营企业参股投资核电项 目，建立健全长效工作机制。国家今年新核准浙江三门、福建霞浦、山东海阳、广东台山、广西防城港等5个核 ...

Core Viewpoint - The innovative pharmaceutical concept stocks are experiencing significant growth, with notable companies reaching historical highs [1] Group 1: Stock Performance - Xinlitai and Kelun Pharmaceutical both achieved historical highs in stock prices [1] - Yangguang Nuohe is approaching a 20% daily limit increase [1] - Zhongsheng Pharmaceutical previously hit a daily limit increase [1] - Haichen Pharmaceutical, Beida Pharmaceutical, and Hongbo Pharmaceutical saw stock prices rise over 10% [1] - Shutaishen, Haixiang Pharmaceutical, Tigermed, and Huahai Pharmaceutical experienced stock price increases of over 5% [1]